Editorials

Transplantation for therapy-related, TP53-mutated myelodysplastic syndrome – not because we can, but because we should

Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Vol. 102 No. 12 (2017): December, 2017 https://doi.org/10.3324/haematol.2017.181180